Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01995 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Adeline Palisse und 33 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry, Oncology, R&D, Acerta Pharma B.V., A member of the AstraZeneca Group, Oss 5349 AB, The Netherlands. Hauptthemen laut MEDLINE: Drug Discovery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
BFL1, a member of the antiapoptotic BCL2 family, has been relatively understudied compared to its counterparts despite evidence of its overexpression in various hematological malignancies. Across two articles, we describe the development of BFL1 in vivo tools. The first article describes the hit identification from a covalent fragment library and the subsequent evolution from the hit to compound 6.22 This work reports the structure-based optimization of compound 6 into a series of BFL1 inhibitors selective over the other BCL2 family members, with low nanomolar cellular activity when combined with AZD5991, exemplified by compound 20. Compound 20 demonstrated a cell death phenotype in SUDHL1 and OCILY10 cell lines and in the in vivo study, BFL1 stabilization and cleaved caspase 3 activation were observed in a dose-dependent manner. In addition, the enzymatic turnover studies with the BFL1 protein showed that compound 20 stabilized the protein, extending the half-life to 10.8 h.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicinal Chemistry, Oncology, R&D, Acerta Pharma B.V., A member of the AstraZeneca Group, Oss 5349 AB, The Netherlands.
- Bioscience, Oncology, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.
- Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
- Bioscience, Oncology, R&D, Acerta B.V., A member of the AstraZeneca Group, Oss 5349 AB, The Netherlands.
- Chemical Biology and Proteomics, Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.
- DMPK, AstraZeneca, Cambridge CB2 0AA, U.K.
ORCID-Profile: Adeline Palisse, Matthew A Cottee, Simon C C Lucas, Vasudev Kantae, Michael J White
Zitieren
APA
Palisse, A., Cheung, T., Blokhuis, A., Cogswell, T., Martins, B. S., Riemens, R., Schellekens, R., Battocchio, G., Jansen, C., Cottee, M. A., Ornell, K., Sacchetto, C., Leon, L., van Hoek-Emmelot, M., Bostock, M., Brauer, B. L., Beaumont, K., Lucas, S. C. C., Ahmed, S., …, & Kinzel, O. (2024). Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01995
Vancouver
Palisse A, Cheung T, Blokhuis A, Cogswell T, Martins BS, Riemens R, et al. Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01995
BibTeX
@article{Palisse2024,
author = {Palisse, Adeline and Cheung, Tony and Blokhuis, Aileen and Cogswell, Thomas and Martins, Bruna S and Riemens, Rick and Schellekens, Rick and Battocchio, Giovanni and Jansen, Chimed and Cottee, Matthew A and Ornell, Kimberly and Sacchetto, Claudia and Leon, Leonardo and van Hoek-Emmelot, Maaike and Bostock, Mark and Brauer, Brooke Leann and Beaumont, Kevin and Lucas, Simon C C and Ahmed, Samiyah and Blackwell, J Henry and Börjesson, Ulf and Gohlke, Andrea and Gramatikov, Iva Monique T and Hargreaves, David and van Hoeven, Vera and Kantae, Vasudev and Kupcova, Lea and Milbradt, Alexander G and Seneviratne, Uthpala and Su, Nancy and Vales, John and Wang, Haiyun and White, Michael J and Kinzel, Olaf},
title = {Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01995}
}
EUVIMED